NanoViricides, Inc. (NNVC)

NYSEAMERICAN: NNVC · Real-Time Price · USD
1.500
-0.070 (-4.46%)
May 30, 2025, 1:27 PM - Market open
-4.46%
Market Cap 23.46M
Revenue (ttm) n/a
Net Income (ttm) -9.73M
Shares Out 15.64M
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 103,521
Open 1.550
Previous Close 1.570
Day's Range 1.510 - 1.615
52-Week Range 0.940 - 3.590
Beta 0.95
Analysts n/a
Price Target n/a
Earnings Date May 15, 2025

About NNVC

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, whic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 7
Stock Exchange NYSEAMERICAN
Ticker Symbol NNVC
Full Company Profile

Financial Performance

Financial Statements

News

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

SHELTON, CT / ACCESS Newswire / May 28, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus ...

2 days ago - Accesswire

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), comments on the new COVID Vaccine policy adopted by the US FDA.

8 days ago - Accesswire

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

NanoViricides Explains Its Drug Strategy for Combating Viral Infections and Pandemics SHELTON, CT / ACCESS Newswire / May 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (t...

16 days ago - Accesswire

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

Shelton, Connecticut--(Newsfile Corp. - May 5, 2025) - NanoViricides, Inc. (NYSE American: NNVC), (the "Company"), a leading clinical stage global pioneer in the development of broad-spectrum antivira...

25 days ago - Newsfile Corp

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

SHELTON, CT / ACCESS Newswire / April 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum ant...

4 weeks ago - Accesswire

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

SHELTON, CT / ACCESS Newswire / April 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum ant...

6 weeks ago - Accesswire

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

SHELTON, CT / ACCESS Newswire / March 11, 2025 / NanoViricides, Inc. (the "Company")(NYSE American:NNVC), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that th...

2 months ago - Accesswire

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

SHELTON, CT / ACCESS Newswire / March 4, 2025 / The HHS Department Secretary Robert F. Kennedy Jr. wrote an Opinion piece in the FoxNews entitled "Measles outbreak is call to action for all of us".

3 months ago - Accesswire

NanoViricides, Inc. Has Filed its Quarterly Report

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu SHELTON, CT / ACCESS Newswire / February 19, 2025 / NanoViricides, Inc. (NYSE...

3 months ago - Accesswire

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum...

3 months ago - Accesswire

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

SHELTON, CT / ACCESS Newswire / January 29, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the vi...

4 months ago - Accesswire

NanoViricides Engages CRO for Phase II Clinical Trial

SHELTON, CT / ACCESS Newswire / January 27, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phas...

4 months ago - Accesswire

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that it is prese...

4 months ago - Accesswire

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), comments on the many viruses that could cause pandemics that are go...

5 months ago - Accesswire

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a pote...

5 months ago - Accesswire

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30...

7 months ago - Accesswire

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that A...

7 months ago - Accesswire

NanoViricides President Dr. Diwan to Present at the PODD Conference

SHELTON, CT / ACCESSWIRE / October 22, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that An...

7 months ago - Accesswire

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

SHELTON, CT / ACCESSWIRE / October 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that A...

8 months ago - Accesswire

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT / ACCESSWIRE / October 8, 2024 / NanoViricides...

8 months ago - Accesswire

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, ...

8 months ago - Accesswire

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.: NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today tha...

8 months ago - Accesswire

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

SHELTON, CT / ACCESSWIRE / August 26, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it i...

9 months ago - Accesswire

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -
A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

SHELTON, CT / ACCESSWIRE / August 19, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update ...

10 months ago - Accesswire

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

SHELTON, CT / ACCESSWIRE / August 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update o...

10 months ago - Accesswire